| Total | IFX | ETA | ADA |
---|---|---|---|---|
Number of patients | 220 | 32 | 137 | 51 |
ASAS20 responders at three months | 68% | 80% | 66% | 65% |
(number of patients) | (145 of 214) | (24 of 30) | (88 of 133) | (33 of 51) |
ASAS20 responders at six months | 63% | 71% | 66% | 51% |
(number of patients) | (132 of 209) | (22 of 31) | (86 of 131) | (24 of 47) |
ASAS40 responders at three months | 49% | 63% | 47% | 45% |
(number of patients) | (104 of 214) | (19 of 30) | (62 of 133) | (23 of 51) |
ASAS40 responders at six months | 46% | 52% | 48% | 38% |
(number of patients) | (97 of 209) | (16 of 31) | (63 of 131) | (18 of 47) |
BASDAI50 responders at three months | 49% | 60% | 46% | 51% |
(number of patients) | (105 of 214) | (18 of 30) | (61 of 133) | (26 of 51) |
BASDAI50 responders at six months | 50% | 48% | 51% | 47% |
(number of patients) | (104 of 209) | (15 of 31) | (67 of 131) | (22 of 47) |
One-year drug survival | 71% | 76% | 72% | 65% |
(number of patients) | (136 of 192) | (22 of 29) | (88 of 123) | (26 of 40) |
Two-year drug survival | 66% | 70% | 69% | 48% |
(number of patients) | (97 of 148) | (19 of 27) | (66 of 96) | (12 of 25) |